<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01929759</url>
  </required_header>
  <id_info>
    <org_study_id>NeuroHIV001</org_study_id>
    <nct_id>NCT01929759</nct_id>
  </id_info>
  <brief_title>Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen</brief_title>
  <official_title>Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we will use a multi-modal imaging approach of MRS and fMRI to comprehensively
      assess the biological changes in the brain associated with EFV-based regimen (EFV/FTC/TDF),
      specifically alterations in the brain circuitry, function and local neurochemistry, and their
      correlation with neuropsychological function. In a cohort of HIV-infected patients who are
      clinically stable on the commonly use regimen of EFV/emtricitabine (FTC)/truvada (TDF) or
      Atripla, we propose to replace the EFV component with a new integrase inhibitor, elvitegravir
      (EVG) boosted with cobicistat (COBI), given as the EVG/COBI/FTC/TDF Single Tablet Regimen
      (STR) to evaluate the EFV-related neural alterations. This is a multidisciplinary study which
      involves a team of infectious disease experts in the field of HIV, neuroradiologists with
      expertise in fMRI and MRS techniques to study various central nervous system and psychiatric
      disorders and a psychiatrist with experience and expertise in research on abnormalities of
      affective and motivational processing in the context of neuropsychiatric disorders. We will
      utilize the established clinical research platform in the Infectious Disease outpatient
      clinical practice at the Brigham and Women's Hospital, where there is currently have many
      ongoing HIV-related studies and a large panel of HIV-infected patients motivated to be
      involved in clinically relevant research. We propose to use advanced neuroimaging to measure
      biologically changes in the brain associated with long-term EFV use with the following
      specific aims:

        1. Determine changes in neurometabolites measured by MRS in the brain associated with
           long-term EFV use

        2. Assess for alterations in neural activity correlated with affective symptoms associated
           with EFV vs STR use using fMRI, and their associations with changes in neurometabolites
           assessed by MRS, and with changes in cognition assessed by Trail Making and Digit
           Substitution Tests.

        3. Determine changes in emotion, cognition and sleep quality after switching from EFV to
           STR, and how they correlate with subject treatment preference.

      This clinical study will extend our current understanding of EFV neurotoxicity by further
      defining the nature of these biological changes. Further elucidation of the neurobiological
      underpinnings of EFV-induced CNS toxicity will have clinical relevance in improving the
      quality of life and drug adherence of HIV-infected patients on ART, especially among older
      patients or those with baseline neuropsychiatric disorders, whom at baseline are more
      vulnerable to neurocognitive decline from long-term HIV infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Treatment switch study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Neurometabolites Based on Magnetic Resonance Spectroscopy (MRS)</measure>
    <time_frame>week 0 to week 8</time_frame>
    <description>Assess the change in levels of neuro-metabolites measured by MRS from week 0 (before switching to the efavirenz-based therapy) and then at week 8 (after completing 9 weeks of integrase-inhibitor based regimen with Stribild). Two areas of the brain: 1) posterior cingulate gyrus and 2) anterior cingulate will be assessed for the levels of brain Cr, GABA and GLU.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neural Activation Networks Using Functional Magnetic Resonance Imaging (fMRI)</measure>
    <time_frame>week 0 and week 8</time_frame>
    <description>Assess changes in neural activation correlated with affective disturbances associated with efavirenz-based therapy using fMRI employing an Emotional Word/Go-NoGo task paradigm that probes affective symptomatologies typical with EFV use, specifically anxiety/dysphoria and affective dysregulation and their association with changes in cognitive function. Four brain regions of interests (ROIs) are specified to show the differential frontal-limbic activation patterns in the task-evoked neural responses to the 3 linear contrasts of Pre-switch / Post-switch / Pre- vs. Post-switch: [Negative Word vs. Neutral Word] x [No-Go Trial Block vs. Go Trial Block]: anterior Frontal Pole (aFP), posterior Cingulate Gyrus (pCG), dorsal anterior Cingulate Gyrus (daCG), Left Hippocampus (LHC). A linear mixed-effects model is utilized to examine the effect sizes of the key Regimen/Condition contrasts, with the Subject factor as the random-effect and Age incorporated as a co-variate of no interest.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Other Neurometabolite Measured by MRS Between Week 0 and Week 8</measure>
    <time_frame>week 0 to week 8</time_frame>
    <description>Use MRS to evaluate a fuller panel of known neurometabolites (in addition to the primary endpoints) between week 0 and week 8 to identify prominent and significant changes associated with EFV use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Changes</measure>
    <time_frame>week 0 and week 8</time_frame>
    <description>Assess for changes in cognitive and affective function prior to and after switching off EFV-based regimen. Indexes used to access neurocognitive changes included:
Wechsler Adult Intelligence Scale (WAIS-R) Digital Symbol Substitution Test: sensitive to brain damage, dementia, age and depressive changes. Range of 0-100, the higher the score the better the person's performance
Hamilton Rating Scale for Depression (HAMD): Measure of depression. Score of 0-7 is normal, score of &gt;20 is moderate/severe depression
Depression Anxiety Stress Scale (DASS-21) the lower the score, the less severe depression, anxiety and stress. Scale range of 0-63
Frontal Systems Behavior Scale (FRSBE): Increased score indicates greater behavioral impairment associated with frontal systems, range 37.2 to 186
6. Spielberger state trait anxiety inventory (STAI): the higher the score the greater then anxiety level, range of 20 to 80.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Lipid Profile</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measure the change in fasting lipid panel prior to and after switching off EFV-based regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality</measure>
    <time_frame>week 0 and week 8</time_frame>
    <description>Assess for changes in sleep pattern and quality prior to and after switching off EFV-based regimen through a self-administered Pittsburg Sleep Quality Index (PSQI). Measure consists of 19 items with each weighted on 0-3 scale and the sum produces a total score, which ranges from 0-21. The lower the score the healthier the sleep quality; minimum Score = 0 (better); maximum Score = 21 (worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ART Regimen Preference</measure>
    <time_frame>week 0 and week 8</time_frame>
    <description>Evaluate patient preference in ART regimen (Atripla, EFV/FTC/TDF versus EVG/COBI/FTC/TDF) through a self-administered questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Immune Activation</measure>
    <time_frame>week 0 and week 8</time_frame>
    <description>Change in markers of immune activation and inflammation associated with change to Stibild: sCD14, IP-10,sCD163, IL-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of EFV and Its Metabolites</measure>
    <time_frame>week 0 and week 8</time_frame>
    <description>Level of EFV (efavirenz) in Atripla and its two known metabolites known to cause cerebral side effects, 7-hydroxy (OH) EFV and 8-OH EFV, were measured in the plasma prior to switch off Atripla and after 8 weeks of RAL-based regimen (no EFV).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>HIV Disease</condition>
  <arm_group>
    <arm_group_label>Drug switching</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)</intervention_name>
    <description>Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks</description>
    <arm_group_label>Drug switching</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic HIV-infected individuals on suppressive regimen with EFV/FTC/TDF, for at least
             6 months

          -  Undetectable HIV-1 RNA virus load for at least 6 months

          -  No co-infections with active hepatitis B and C

          -  Presence of at least moderate symptoms on 2 out of 3 subcores on the DASS

          -  No known active HIV-related and non-HIV related CNS infections

          -  Estimated glomerular filtration rate (EGFR) &gt;60 ml/min

          -  Consent to switching to EVG/COBI/FTC/TDF

          -  Ages 18 - 65

        Exclusion Criteria:

          -  History of CNS opportunistic infections or active CNS infections

          -  History of severe psychiatric disorder (excluding depression and anxiety)

          -  History of chronic neurological disorders, such as epilepsy or multiple sclerosis

          -  History of or current significant substance abuse or dependence and/or heavy alcohol
             use (&gt;12 oz/wk)

          -  Any women who may be pregnant (positive urine pregnancy test or unprotected sex in 2
             weeks prior to scan) or known to be pregnant

          -  Contraindications to undergoing fMRI, including metallic implants, claustrophobia, and
             medical conditions or medications that significantly affect cerebral blood flow or
             function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2013</study_first_submitted>
  <study_first_submitted_qc>August 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2013</study_first_posted>
  <results_first_submitted>March 27, 2017</results_first_submitted>
  <results_first_submitted_qc>July 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 28, 2017</results_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Nina Lin, MD</investigator_full_name>
    <investigator_title>Instructor in Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>neurocognitive symptoms</keyword>
  <keyword>efavirenz</keyword>
  <keyword>elvitegravir</keyword>
  <keyword>neurometabolites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Cobicistat</mesh_term>
    <mesh_term>Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Drug Switching</title>
          <description>Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir): Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Drug Switching</title>
          <description>Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir): Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline measures for Neurometabolites Based on MRS</title>
          <description>The arbitrary units are expressed as the output from MRS software. While similar to concentration (mM) due to assumptions in the software, it is best expressed as arbitrary units for comparison from baseline to the second time point.</description>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Posterior cingulate creatine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.09" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior cingulate glutamate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.36" spread="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior cingulate GABA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.99" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior cingulate creatine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.06" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior cingulate glutamate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.16" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior cingulate GABA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.21" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Neurometabolites Based on Magnetic Resonance Spectroscopy (MRS)</title>
        <description>Assess the change in levels of neuro-metabolites measured by MRS from week 0 (before switching to the efavirenz-based therapy) and then at week 8 (after completing 9 weeks of integrase-inhibitor based regimen with Stribild). Two areas of the brain: 1) posterior cingulate gyrus and 2) anterior cingulate will be assessed for the levels of brain Cr, GABA and GLU.</description>
        <time_frame>week 0 to week 8</time_frame>
        <population>The arbitrary units are expressed as the output from MRS software. While similar to concentration (mM) due to assumptions in the software, it is best expressed as arbitrary units for comparison from week 0 to week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Switching</title>
            <description>Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir): Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Neurometabolites Based on Magnetic Resonance Spectroscopy (MRS)</title>
          <description>Assess the change in levels of neuro-metabolites measured by MRS from week 0 (before switching to the efavirenz-based therapy) and then at week 8 (after completing 9 weeks of integrase-inhibitor based regimen with Stribild). Two areas of the brain: 1) posterior cingulate gyrus and 2) anterior cingulate will be assessed for the levels of brain Cr, GABA and GLU.</description>
          <population>The arbitrary units are expressed as the output from MRS software. While similar to concentration (mM) due to assumptions in the software, it is best expressed as arbitrary units for comparison from week 0 to week 8.</population>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Posterior Cingulate Creatine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.61" spread="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior Cingulate Glutamate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.54" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior Cingulate GABA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.71" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior Cingulate Creatine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.08" spread="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior Cingulate Glutamate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.16" spread="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior Cingulate GABA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Neural Activation Networks Using Functional Magnetic Resonance Imaging (fMRI)</title>
        <description>Assess changes in neural activation correlated with affective disturbances associated with efavirenz-based therapy using fMRI employing an Emotional Word/Go-NoGo task paradigm that probes affective symptomatologies typical with EFV use, specifically anxiety/dysphoria and affective dysregulation and their association with changes in cognitive function. Four brain regions of interests (ROIs) are specified to show the differential frontal-limbic activation patterns in the task-evoked neural responses to the 3 linear contrasts of Pre-switch / Post-switch / Pre- vs. Post-switch: [Negative Word vs. Neutral Word] x [No-Go Trial Block vs. Go Trial Block]: anterior Frontal Pole (aFP), posterior Cingulate Gyrus (pCG), dorsal anterior Cingulate Gyrus (daCG), Left Hippocampus (LHC). A linear mixed-effects model is utilized to examine the effect sizes of the key Regimen/Condition contrasts, with the Subject factor as the random-effect and Age incorporated as a co-variate of no interest.</description>
        <time_frame>week 0 and week 8</time_frame>
        <population>8 of 10 enrolled patients passed QA testing to be included in the final analyses. The 3 linear contrasts of Pre-switch/Post-switch/Pre- vs. Post-switch: [Neg vs.Neu] x [No-Go vs. Go] are reported as z-score (standardized effect size measures with SD=1). Z-score is obtained for each subject, group Z-score is obtained via a mixed-effects model.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Switching</title>
            <description>Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir): Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Neural Activation Networks Using Functional Magnetic Resonance Imaging (fMRI)</title>
          <description>Assess changes in neural activation correlated with affective disturbances associated with efavirenz-based therapy using fMRI employing an Emotional Word/Go-NoGo task paradigm that probes affective symptomatologies typical with EFV use, specifically anxiety/dysphoria and affective dysregulation and their association with changes in cognitive function. Four brain regions of interests (ROIs) are specified to show the differential frontal-limbic activation patterns in the task-evoked neural responses to the 3 linear contrasts of Pre-switch / Post-switch / Pre- vs. Post-switch: [Negative Word vs. Neutral Word] x [No-Go Trial Block vs. Go Trial Block]: anterior Frontal Pole (aFP), posterior Cingulate Gyrus (pCG), dorsal anterior Cingulate Gyrus (daCG), Left Hippocampus (LHC). A linear mixed-effects model is utilized to examine the effect sizes of the key Regimen/Condition contrasts, with the Subject factor as the random-effect and Age incorporated as a co-variate of no interest.</description>
          <population>8 of 10 enrolled patients passed QA testing to be included in the final analyses. The 3 linear contrasts of Pre-switch/Post-switch/Pre- vs. Post-switch: [Neg vs.Neu] x [No-Go vs. Go] are reported as z-score (standardized effect size measures with SD=1). Z-score is obtained for each subject, group Z-score is obtained via a mixed-effects model.</population>
          <units>z-score</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PreVsPostXNegVsNeuXNoGoVsGo: aFP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PreVsPostXNegVsNeuXNoGoVsGo: pCG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PreVsPostXNegVsNeuXNoGoVsGo: daCG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PreVsPostXNegVsNeuXNoGoVsGo:LHC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre: NegVsNeuXNoGoVsGo: aFP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre: NegVsNeuXNoGoVsGo:pCG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre: NegVsNeuXNoGoVsGo: daCG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre: NegVsNeuXNoGoVsGo: LHC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post: NegVsNeuXNoGoVsGo: aFP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post: NegVsNeuXNoGoVsGo: pCG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post: NegVsNeuXNoGoVsGo: daCG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post: NegVsNeuXNoGoVsGo: LHC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Other Neurometabolite Measured by MRS Between Week 0 and Week 8</title>
        <description>Use MRS to evaluate a fuller panel of known neurometabolites (in addition to the primary endpoints) between week 0 and week 8 to identify prominent and significant changes associated with EFV use.</description>
        <time_frame>week 0 to week 8</time_frame>
        <population>The arbitrary units are expressed as the output from MRS software. While similar to concentration (mM) due to assumptions in the software, it is best expressed as arbitrary units for comparison from week 0 to week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Switching</title>
            <description>Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir): Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Other Neurometabolite Measured by MRS Between Week 0 and Week 8</title>
          <description>Use MRS to evaluate a fuller panel of known neurometabolites (in addition to the primary endpoints) between week 0 and week 8 to identify prominent and significant changes associated with EFV use.</description>
          <population>The arbitrary units are expressed as the output from MRS software. While similar to concentration (mM) due to assumptions in the software, it is best expressed as arbitrary units for comparison from week 0 to week 8.</population>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Posterior cingulate glutathione</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior cingulate aspartate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior cingulate glutathione</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anterior cingulate aspartate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Changes</title>
        <description>Assess for changes in cognitive and affective function prior to and after switching off EFV-based regimen. Indexes used to access neurocognitive changes included:
Wechsler Adult Intelligence Scale (WAIS-R) Digital Symbol Substitution Test: sensitive to brain damage, dementia, age and depressive changes. Range of 0-100, the higher the score the better the person's performance
Hamilton Rating Scale for Depression (HAMD): Measure of depression. Score of 0-7 is normal, score of &gt;20 is moderate/severe depression
Depression Anxiety Stress Scale (DASS-21) the lower the score, the less severe depression, anxiety and stress. Scale range of 0-63
Frontal Systems Behavior Scale (FRSBE): Increased score indicates greater behavioral impairment associated with frontal systems, range 37.2 to 186
6. Spielberger state trait anxiety inventory (STAI): the higher the score the greater then anxiety level, range of 20 to 80.</description>
        <time_frame>week 0 and week 8</time_frame>
        <population>Several Indexes were used to access neurocognitive changes: WAIS, HAMD, FRSBE, DASS-21, STAI.
Participants were given these tests prior to and after drug switch.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Switching</title>
            <description>Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir): Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Changes</title>
          <description>Assess for changes in cognitive and affective function prior to and after switching off EFV-based regimen. Indexes used to access neurocognitive changes included:
Wechsler Adult Intelligence Scale (WAIS-R) Digital Symbol Substitution Test: sensitive to brain damage, dementia, age and depressive changes. Range of 0-100, the higher the score the better the person's performance
Hamilton Rating Scale for Depression (HAMD): Measure of depression. Score of 0-7 is normal, score of &gt;20 is moderate/severe depression
Depression Anxiety Stress Scale (DASS-21) the lower the score, the less severe depression, anxiety and stress. Scale range of 0-63
Frontal Systems Behavior Scale (FRSBE): Increased score indicates greater behavioral impairment associated with frontal systems, range 37.2 to 186
6. Spielberger state trait anxiety inventory (STAI): the higher the score the greater then anxiety level, range of 20 to 80.</description>
          <population>Several Indexes were used to access neurocognitive changes: WAIS, HAMD, FRSBE, DASS-21, STAI.
Participants were given these tests prior to and after drug switch.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-switch WAIS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" spread="11.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch WAIS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.4" spread="12.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch FRSBE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" spread="10.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch FRSBE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4" spread="13.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch HAMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch HAMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch DASS depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="8.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch DASS depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-swtich STAI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch STAI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" spread="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Lipid Profile</title>
        <description>Measure the change in fasting lipid panel prior to and after switching off EFV-based regimen.</description>
        <time_frame>8 weeks</time_frame>
        <population>Change in fasting lipid profile was measured: total cholesterol, HDL and LDL levels.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Switching</title>
            <description>Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir): Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Lipid Profile</title>
          <description>Measure the change in fasting lipid panel prior to and after switching off EFV-based regimen.</description>
          <population>Change in fasting lipid profile was measured: total cholesterol, HDL and LDL levels.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-switch Total cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.8" spread="24.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch Total cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.5" spread="20.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" spread="16.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" spread="19.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.1" spread="22.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" spread="19.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch triglyceride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.3" spread="50.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch triglyceride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" spread="30.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality</title>
        <description>Assess for changes in sleep pattern and quality prior to and after switching off EFV-based regimen through a self-administered Pittsburg Sleep Quality Index (PSQI). Measure consists of 19 items with each weighted on 0-3 scale and the sum produces a total score, which ranges from 0-21. The lower the score the healthier the sleep quality; minimum Score = 0 (better); maximum Score = 21 (worse).</description>
        <time_frame>week 0 and week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug Switching</title>
            <description>Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir): Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality</title>
          <description>Assess for changes in sleep pattern and quality prior to and after switching off EFV-based regimen through a self-administered Pittsburg Sleep Quality Index (PSQI). Measure consists of 19 items with each weighted on 0-3 scale and the sum produces a total score, which ranges from 0-21. The lower the score the healthier the sleep quality; minimum Score = 0 (better); maximum Score = 21 (worse).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-switch PSQI index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch PSQI index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ART Regimen Preference</title>
        <description>Evaluate patient preference in ART regimen (Atripla, EFV/FTC/TDF versus EVG/COBI/FTC/TDF) through a self-administered questionnaire.</description>
        <time_frame>week 0 and week 8</time_frame>
        <population>Patients were surveyed at the end of the study with a single question regarding their ART preference. They are asked to pick one of the 3 answers: 1. prefer Atripla, 2. prefer the new drug (Stribild) or 3. no preference. The number of patients who would like to switch to study drug, Stribild, are indicated by the percentage.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Switching</title>
            <description>Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir): Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>ART Regimen Preference</title>
          <description>Evaluate patient preference in ART regimen (Atripla, EFV/FTC/TDF versus EVG/COBI/FTC/TDF) through a self-administered questionnaire.</description>
          <population>Patients were surveyed at the end of the study with a single question regarding their ART preference. They are asked to pick one of the 3 answers: 1. prefer Atripla, 2. prefer the new drug (Stribild) or 3. no preference. The number of patients who would like to switch to study drug, Stribild, are indicated by the percentage.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Prefers Stribld</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Prefers Atripla</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No preference</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Immune Activation</title>
        <description>Change in markers of immune activation and inflammation associated with change to Stibild: sCD14, IP-10,sCD163, IL-6)</description>
        <time_frame>week 0 and week 8</time_frame>
        <population>Inflammatory markers were measured pre- and post-drug switch from Atripla to Stibild.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Switching</title>
            <description>Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir): Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Immune Activation</title>
          <description>Change in markers of immune activation and inflammation associated with change to Stibild: sCD14, IP-10,sCD163, IL-6)</description>
          <population>Inflammatory markers were measured pre- and post-drug switch from Atripla to Stibild.</population>
          <units>pg/ML</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-switch sCD14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3329000" spread="566684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch sCD14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2879000" spread="867793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch IP-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237.3" spread="204.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch IP-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224.2" spread="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch sCD163</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="732000" spread="559000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch sCD163</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="599500" spread="319200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch MCP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.2" spread="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch MCP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.39" spread="43.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.255" spread="0.5921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.301" spread="0.7115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-switch TNFR1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="833.2" spread="222.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-switch TNFR1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="878.1" spread="198.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of EFV and Its Metabolites</title>
        <description>Level of EFV (efavirenz) in Atripla and its two known metabolites known to cause cerebral side effects, 7-hydroxy (OH) EFV and 8-OH EFV, were measured in the plasma prior to switch off Atripla and after 8 weeks of RAL-based regimen (no EFV).</description>
        <time_frame>week 0 and week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug Switching</title>
            <description>Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir): Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of EFV and Its Metabolites</title>
          <description>Level of EFV (efavirenz) in Atripla and its two known metabolites known to cause cerebral side effects, 7-hydroxy (OH) EFV and 8-OH EFV, were measured in the plasma prior to switch off Atripla and after 8 weeks of RAL-based regimen (no EFV).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number with detectable 7-OH and 8-OH (pre-switch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number with detectable 7-OH and 8-OH (post-switch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Drug Switching</title>
          <description>Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir): Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One participant did not have repeat fMRI because the pre-switch fMRI was not done correctly. The patient did not fully understand the tasks to be performed, therefore no repeat follow up fMRI was done without the comparator study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Nina Lin</name_or_title>
      <organization>Boston Medical Center, Boston University School of Medicine</organization>
      <phone>617-414-5242</phone>
      <email>nina.lin@bmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

